Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

Lincolnshire, Ill., April 21, 2020 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL...